Stephanie Vrede

PURE AND MIXED CLEAR CELL CARCINOMA 91 4 Table 4B. Disease-specific survival (DSS) by histology in univariable and multivariable Cox regression analysis. Univariable Multivariable HR 95% CI P HR 95% CI P Histology Pure Mixed 0.32 (0.10 – 1.04) 0.06 1.05 (0.20 – 5.60) 0.95 Age 1.00 (0.94 – 1.07) 0.91 - FIGO I/II III/IV 7.23 (1.99 – 26.3) 0.01 3.84 (0.83 – 17.8) 0.09 TCGA TP53 wildtype POLE mutated MSI TP53 mutated No events 0.54 (0.05 –6.00) 7.15 (1.51 – 33.9) - 0.62 0.01 No events 0.93 (0.07 – 11.8) 6.50 (1.24 – 34.2) 0.95 0.03 Abbreviations: DSS, disease-specific survival; EC, endometrial cancer; HR, hazard ratio; CI, confidence interval; POLE, Polymerase epsilon; MSI, Microsatellite instability; TP53, Tumor protein; NSMP, No-specific molecular profile, LVSI, lymphovascular space invasion; FIGO, Federation International of Gynecology and Obstetrics. Table 4C. Progression-free survival (RFS) by histology in univariable and multivariable Cox regression analysis. Univariable Multivariable HR 95% CI P HR 95% CI P Histology Pure Mixed 0.31 (0.10 – 0.99) 0.05 0.59 (0.14 – 2.56) 0.49 Age 0.96 (0.91 – 1.02) 0.22 - FIGO I/II III/IV 8.58 (2.39 – 30.8) 0.01 4.92 (1.06 – 22.9) 0.04 TCGA TP53 wildtype POLE mutated MSI TP53 mutated No events 0.32 (0.04 – 2.89) 3.29 (0.95 – 11.5) - 0.31 0.06 No events 0.98 (0.08 – 11.9) 2.93 (0.80 – 10.7) - 0.99 0.10 Abbreviations: DSS, disease-specific survival; EC, endometrial cancer; HR, hazard ratio; CI, confidence interval; POLE, Polymerase epsilon; MSI, Microsatellite instability; TP53, Tumor protein; NSMP, No-specific molecular profile, LVSI, lymphovascular space invasion; FIGO, Federation International of Gynecology and Obstetrics.

RkJQdWJsaXNoZXIy MTk4NDMw